GE Healthcare and Parker Domnick Hunter Announce Distribution And Collaboration Agreements In Biopharmaceutical Purification

Companies to Serve Biopharmaceutical Market with Advanced Microfiltration Cartridges and Devices

Chalfont St. Giles, UK, and Newcastle, UK - GE Healthcare and Parker domnick hunter, a division of Parker Hannifin announced that they have entered into an exclusive agreement for the supply and distribution of products for biopharmaceutical purification. Under the terms of the agreement, GE Healthcare will have exclusive global rights to market a new range of microfiltration cartridges and disposable filters manufactured by Parker domnick hunter. Financial terms were not disclosed.

The new line of disposable filters for liquid filtration applications in biopharmaceutical manufacture will be marketed by GE Healthcare’s global sales and marketing organization under the ULTA™ brand. The products increase the range of technologies available for the purification of vaccines, antibodies and other biomolecules.

"This agreement allows us to expand the range of products for biopharmaceutical purification that we are able to offer our customers” said Ann O’Hara, General Manager of Bioprocess for GE Healthcare. "Building on our reputation as a supplier of cutting edge technologies, the ULTA™ line of normal flow cartridges will be a significant addition to our purification portfolio”.

"We developed an outstanding line of cartridge filters with an eye to making significant in roads into the pharmaceutical market, expanding on our past successes in this area." said Jeff Porter, Managing Director, Process Division, Europe at Parker domnick hunter. "We are very excited about the prospects of this agreement, which enables us to bring our advanced purification technologies to the biopharmaceutical production industry."

Parker domnick hunter will continue to market its own brand of air and gas filters to the biopharmaceutical industry.

Under a separate joint technology development agreement the two companies will collaborate in the development of new technologies for protein purification, drawing from each other's strengths in separation and purification techniques, membrane production manufacturing and market insights.

SOURCE: Cytiva